Been looking at some biotech plays lately and there's one that's been catching my attention. Iovance Biotherapeutics—ticker IOVA—is a penny stock that could genuinely reshape a portfolio if things break right over the next decade.

Here's the thing: their lead product Amtagvi just got approval for melanoma back in early 2024. It's basically a personalized cancer therapy manufactured from patients' own cells. Sounds wild, right? The commercial traction has actually been solid despite some stock price weakness. FY2025 revenue hit $263.5 million, up over 60% year-over-year. Most of that's coming from Amtagvi.

They're not just sitting on melanoma either. Amtagvi is being studied across multiple cancer types. They got Fast Track Designation from the FDA for non-small cell lung cancer treatment, which basically means the development process gets accelerated. They're also pushing for approvals in the EU, UK, and Australia. If they can crack into a massive market like NSCLC, the upside could be substantial.

But here's where it gets tricky. The manufacturing process is genuinely complex. You've got to extract patients' cells, manufacture the treatment individually for each person, then administer it via IV after chemotherapy. The whole process takes about 34 days. It can only be given at specialized centers with trained staff. That's expensive infrastructure, and it's going to weigh on profitability for a while.

There are also the standard biotech risks—clinical setbacks could tank the stock, regulatory hurdles could delay approvals, execution could falter. This isn't a play for risk-averse investors.

That said, if Iovance navigates all these obstacles and Amtagvi captures meaningful market share in cancer treatment, shares could absolutely skyrocket. The cancer therapy space is massive, and personalized treatments are getting serious attention. But you need to be comfortable with significant volatility and the real possibility this doesn't work out. Do your homework before touching penny stocks like this one.